A. Czibere

I. Bruns, U. Germing, G. Kobbe, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells

I. Bruns, Ron-Patrick Cadeddu, L. Zerbini, 2012, Annals of Hematology.

Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor

A. von Haeseler, D. Tenen, P. Wernet, 2008, Haematologica.

X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.

R. Haas, A. Giagounidis, M. Aivado, 2006, Blood cells, molecules & diseases.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

H. Rugo, J. Hopkins, Miguel Martín, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

I. Bruns, G. Kobbe, R. Fenk, 2007, Leukemia & lymphoma.

Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials

I. C. Tudor, A. Czibere, J. Litton, 2020, Journal of clinical pharmacology.

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials.

I. C. Tudor, N. Turner, A. Czibere, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial.

I. C. Tudor, A. Czibere, J. Litton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial

I. C. Tudor, A. Czibere, J. Litton, 2020, Journal of clinical pharmacology.

C/EBPα is required for development of dendritic cell progenitors.

K. Akashi, D. Tenen, K. S. A. Wansa, 2013, Blood.

The Nonsteroidal Anti-Inflammatory Drug Exisulind Selectively Induces Apoptosis via JNK in Secondary Acute Myeloid Leukemia after Myelodysplastic Syndrome

T. Libermann, L. Zerbini, R. Haas, 2005, Cell cycle.

Combining Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) as First Salvage Treatment in Patients (PTS) With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Interim-Analysis From the Azarela

N. Kröger, T. Luft, I. Bruns, 2011 .

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

F. Saad, G. Scagliotti, T. Dorff, 2021, The Lancet. Oncology.

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, N. Agarwal, A. Fay, 2020, Journal of Clinical Oncology.

Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes.

C. Steidl, U. Germing, R. Haas, 2005 .

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, C. Higano, K. Fizazi, 2021 .

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

F. Saad, J. Bono, C. Higano, 2020 .

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

F. Saad, J. Bono, C. Higano, 2020 .

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

B. Schoeberl, U. Nielsen, E. Pace, 2018, Clinical Cancer Research.

Dexamethasone modulates BMP‐2 effects on mesenchymal stem cells in vitro

J. Fischer, D. Ayers, A. Czibere, 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Combinatorial Effect of Non-Steroidal Anti-inflammatory Drugs and NF-κB Inhibitors in Ovarian Cancer Therapy

M. Bhasin, T. Libermann, P. Fisher, 2011, PloS one.

A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells.

H. Otu, T. Libermann, P. Fisher, 2006, Cancer research.

Arrest of Cancer Cells Induced Apoptosis and Growth − Anti-inflammatory Drug Associated Gene-7 / Interleukin-24 Mediates Nonsteroidal A Novel Pathway Involving Melanoma Differentiation

H. Otu, T. Libermann, P. Fisher, 2006 .

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design.

J. Carles, N. Agarwal, A. Fay, 2022, Future oncology.

Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.

D. Tenen, J. Zuber, J. A. Pulikkan, 2021, Blood.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

V. Grantcharova, B. Schoeberl, U. Nielsen, 2017, npj Systems Biology and Applications.

Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.

A. Trumpp, I. Bruns, Ron-Patrick Cadeddu, 2012, Blood.

The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway

I. Bruns, Ron-Patrick Cadeddu, L. Zerbini, 2011, Apoptosis.

NF-κB-mediated repression of growth arrest- and DNA-damage-inducible proteins 45α and γ is essential for cancer cell survival

Marie Joseph, Ricardo G. Correa, Towia A. Libermann, 2004 .

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

N. Kröger, I. Bruns, U. Germing, 2010, Bone Marrow Transplantation.

Perspectives of proteomics in acute myeloid leukemia

F. Grall, M. Aivado, A. Czibere, 2006, Expert review of anticancer therapy.

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

N. Kröger, T. Luft, U. Germing, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The tissue inhibitor of metalloproteinases-1 improves migration and adhesion of hematopoietic stem and progenitor cells.

S. Hell, I. Bruns, Ron-Patrick Cadeddu, 2013, Experimental hematology.

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome

H. Otu, T. Libermann, U. Steidl, 2009, International journal of hematology.

T. Libermann, R. Haas, D. Spentzos, 2007, Mechanisms of Ageing and Development.

HEMATOPOIESIS AND STEM CELLS C/EBP a is required for development of dendritic cell progenitors

K. Akashi, D. Tenen, K. S. A. Wansa, 2013 .

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

N. Kröger, Ron-Patrick Cadeddu, U. Germing, 2013, Leukemia.

246PA META-ANALYSIS OF BIOMARKERS IN THREE RANDOMIZED, PHASE 2 STUDIES OF MM-121, A LIGAND-BLOCKING ANTI-ERBB3 ANTIBODY, IN PATIENTS WITH OVARIAN, LUNG, AND BREAST CANCERS.

L. Sequist, G. MacBeath, J. Pearlberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

hematopoietic stem and progenitor cells + derived CD34 - related deregulation of bone marrow - Multiple myeloma

A. Trumpp, Ron-Patrick Cadeddu, U. Steidl, 2013 .

Mass spectrometry-based proteomics and its potential use in haematological research

S. Lehr, R. Haas, A. Czibere, 2009, Archives of physiology and biochemistry.

JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer

Jin-Rong Zhou, T. Libermann, L. Zerbini, 2011, Cell cycle.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan

G. MacBeath, G. Shapiro, Sunil Sharma, 2017, Investigational New Drugs.

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.

I. Bruns, W. Brugger, N. Niederle, 2015, Blood.

Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

N. Agarwal, K. Fizazi, A. Czibere, 2019, Journal of Clinical Oncology.

Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

I. Bruns, G. Kobbe, R. Fenk, 2010, Acta Haematologica.

Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.

D. Tenen, Hong Zhang, G. Martinelli, 2015, Cancer cell.

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

I. Bruns, R. Haas, R. Kronenwett, 2009, Leukemia.

Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.

J. Carles, N. Agarwal, A. Fay, 2018 .

NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival.

Marie Joseph, Jin-Rong Zhou, T. Libermann, 2004, Proceedings of the National Academy of Sciences of the United States of America.

ProteoMiner™ and SELDI-TOF-MS: A robust and highly reproducible combination for biomarker discovery from whole blood serum

S. Hartwig, S. Lehr, R. Haas, 2010, Archives of physiology and biochemistry.

Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations.

I. Bruns, G. Kobbe, R. Fenk, 2009 .

NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo

T. Libermann, L. Zerbini, A. Czibere, 2012, IUBMB life.

Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).

M. Tomasson, S. Iida, M. Mohty, 2022, Journal of Clinical Oncology.

A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.

G. MacBeath, H. Hirte, I. Vergote, 2014 .

Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

W. Symmans, J. Chakrabarti, M. Danso, 2021, Journal of Clinical Oncology.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

S. Trudel, M. Tomasson, S. Iida, 2023, Nature Medicine.

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

I. Bruns, G. Kobbe, R. Fenk, 2009, Leukemia research.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

N. Kröger, T. Luft, I. Bruns, 2013, Leukemia.

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.

M. Tomasson, S. Iida, M. Mohty, 2023, Journal of Clinical Oncology.

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

I. Bruns, G. Kobbe, R. Fenk, 2007 .

U. Germing, R. Haas, M. Aivado, 2009, Leukemia & lymphoma.

NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo

T. Libermann, L. Zerbini, A. Czibere, 2012, IUBMB life.

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

L. Sequist, J. Nieva, F. Shepherd, 2016 .

Y. Bang, J. Bendell, M. Alsina, 2014 .

A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.

J. Soria, A. Adjei, G. Dy, 2013 .

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

W. Symmans, J. Chakrabarti, M. Danso, 2023, The Oncologist.

Hematopoiesis in Chronic Phase CML emerges from Hematopoietic Stem Cells with a Transcriptional Phenotype Resembling Normal Myeloid Progenitor Cells.

I. Bruns, U. Steidl, J. Fischer, 2008 .

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome

H. Otu, T. Libermann, U. Steidl, 2009, International journal of hematology.

Core binding factor leukemia hijacks T-cell prone PU.1 antisense Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter [preprint] promoter [preprint] us know how access to this document benefits you.

J. A. Pulikkan, W. Sperr, A. Czibere, 2021 .

Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor.

I. Bruns, G. Kobbe, R. Fenk, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.